Angewandte Chemie,
Journal Year:
2024,
Volume and Issue:
136(37)
Published: June 17, 2024
Abstract
The
exploration
of
cell‐based
drug
delivery
systems
for
cancer
therapy
has
gained
growing
attention.
Approaches
to
engineering
therapeutic
cells
with
multidrug
loading
in
an
effective,
safe,
and
precise
manner
while
preserving
their
inherent
biological
properties
remain
great
interest.
Here,
we
report
a
strategy
simultaneously
load
multiple
drugs
platelets
one‐step
fusion
process.
We
demonstrate
doxorubicin
(DOX)‐encapsulated
liposomes
conjugated
interleukin‐15
(IL‐15)
could
fuse
achieve
both
cytoplasmic
surface
cytokine
modification
efficiency
over
70
%
within
minutes.
Due
targeting
ability
metastatic
cancers
postoperative
bleeding
sites,
the
engineered
demonstrated
synergistic
effect
suppress
lung
metastasis
recurrence
mouse
B16F10
melanoma
tumor
models.
Advanced Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 10, 2025
Abstract
Cancer
immunotherapy,
which
leverages
immune
system
components
to
treat
malignancies,
has
emerged
as
a
cornerstone
of
contemporary
therapeutic
strategies.
Yet,
critical
concerns
about
the
efficacy
and
safety
cancer
immunotherapies
remain
formidable.
Nanotechnology,
especially
polymeric
nanoparticles
(PNPs),
offers
unparalleled
flexibility
in
manipulation‐from
chemical
composition
physical
properties
precision
control
nanoassemblies.
PNPs
provide
an
optimal
platform
amplify
potency
minimize
systematic
toxicity
broad
spectrum
immunotherapeutic
modalities.
In
this
comprehensive
review,
basics
polymer
chemistry,
state‐of‐the‐art
designs
from
physicochemical
standpoint
for
encompassing
vaccines,
situ
vaccination,
adoptive
T‐cell
therapies,
tumor‐infiltrating
cell‐targeted
antibodies,
cytokine
therapies
are
delineated.
Each
immunotherapy
necessitates
distinctively
tailored
design
strategies
nanoplatforms.
The
extensive
applications
PNPs,
investigation
their
mechanisms
action
enhanced
particularly
focused
on.
profiles
clinical
research
progress
discussed.
Additionally,
forthcoming
developments
emergent
trends
nano‐immunotherapeutics
poised
transform
treatment
paradigms
into
clinics
explored.
Small,
Journal Year:
2024,
Volume and Issue:
20(44)
Published: July 6, 2024
Abstract
Sonodynamic
therapy
(SDT),
featuring
noninvasive,
deeper
penetration,
low
cost,
and
repeatability,
is
a
promising
approach
for
deep‐seated
tumors.
However,
the
general
or
only
utilization
of
SDT
shows
efficiency
unsatisfactory
treatment
outcomes
due
to
complicated
tumor
microenvironment
(TME)
process.
To
circumvent
issues,
three
feasible
approaches
enhancing
SDT‐based
therapeutic
effects,
including
sonosensitizer
optimization,
strategies
conquering
hypoxia
TME,
combinational
are
summarized,
with
particular
focus
on
combination
other
modalities,
chemodynamic
therapy,
photodynamic
photothermal
chemotherapy,
starvation
gas
immunotherapy.
In
end,
current
challenges
in
tumors
discussed
enhanced
effects
provided.
It
envisioned
that
this
review
will
provide
new
insight
into
strategic
design
high‐efficiency
sonosensitizer‐derived
nanotheranostics,
thereby
augmenting
accelerating
potential
clinical
transformation.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 17, 2024
Abstract
Nanotheranostics,
which
integrate
diagnostic
and
therapeutic
functionalities,
offer
significant
potential
for
tumor
treatment.
However,
current
nanotheranostic
systems
typically
involve
multiple
molecules,
each
providing
a
singular
or
function,
leading
to
challenges
such
as
complex
structural
composition,
poor
targeting
efficiency,
lack
of
spatiotemporal
control,
dependence
on
single
modality.
This
study
introduces
NP
RBOXA
,
nanoparticle
functionalized
with
surface‐bound
cRGD
targeted
delivery
α
v
β
3
/α
5
receptors
cells,
achieving
theranostic
integration
by
sequentially
switching
its
irradiation
modes.
Under
808
nm
laser
irradiation,
emits
NIR‐II
fluorescence,
aids
in
identifying
the
nanoparticle's
location
fluorescence
intensity,
thereby
determining
optimal
treatment
window.
Following
this,
mode
switches
ultrasound
at
Ultrasound
induces
generate
reactive
oxygen
species,
promoting
reduction
OXA‐IV
OXA‐II,
turn
triggers
immunogenic
cell
death.
mechanism
enables
combination
sonodynamic
therapy,
chemotherapy,
immunotherapy
The
versatile
design
holds
promise
advancing
precision
oncology
through
enhanced
efficacy
real‐time
imaging
guidance.
Journal of the American Chemical Society,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 7, 2024
Extracellular
and
transmembrane
proteins,
which
account
for
the
products
of
approximately
40%
all
protein-encoding
genes
in
tumors,
play
a
crucial
role
shaping
tumor
immunosuppressive
microenvironment
(TIME).
While
protein
degradation
therapy
has
been
applied
to
membrane
proteins
cancer
cells,
it
rarely
extended
immune
cells.
We
herein
report
polymeric
nanolysosome
targeting
chimera
(nano-LYTAC)
that
undergoes
on
M2
macrophages
generates
sonodynamic
effect
combinational
immunotherapy.
Nano-LYTAC
is
found
have
higher
efficacy
interleukin
4
receptor
(IL-4R)
compared
traditional
inhibitors.
More
importantly,
revealed
nano-LYTAC
function
macrophage
concentration-dependent:
downregulating
CD206
expression
10
(IL-10)
secretion
from
at
low
concentration,
while
triggering
their
apoptosis
high
concentration.
Moreover,
possess
long
retention
(>48
h),
allowing
multiple
treatments
with
single
dose.
Such
synergistic
immunotherapy
mediated
by
effectively
reprograms
TIME
via
inhibiting
functions
regulatory
T
cells
(Tregs),
as
well
promoting
maturation
dendritic
(DCs)
infiltration
effector
(Teffs),
completely
suppressing
growth,
pulmonary
metastasis,
preventing
recurrence
under
preclinical
animal
models.
ACS Nano,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 7, 2025
B-cell
lymphoma
(BCL)
is
a
hematological
malignancy
with
high
heterogeneity
and
represents
an
aggressive
proliferation
of
mature
B-cells.
Despite
the
initial
success
traditional
treatments
for
BCL
in
clinical
trials,
majority
patients
eventually
develop
resistance
to
therapy
have
poor
outcomes.
Epigenetic
dysregulation
major
contributor
pathogenesis
BCL,
therapies
targeting
epigenetic
pathways
promising
alternative
strategy
treating
BCL.
Herein,
we
developed
metal-organic
framework
(MOF)-based
nano-sonosensitizer
ultrasound-driven
cascade
immunotherapy
against
The
was
synthesized
by
encapsulating
copper
complex
m6A-mRNA
demethylase
inhibitor
into
UiO-66-NH2,
which
possesses
Z-scheme
heterostructure
allows
efficient
electron-hole
pair
separation
generating
reactive
oxygen
species
(ROS)
under
ultrasound
activation.
These
CuR@UiO66
sonosensitizers
were
functionalized
mPEG-PO3
anti-CD19
antibody,
resulting
CRUPPA19
particles
could
specifically
accumulate
tissue
also
target
cells
that
infiltrated
bone
marrow.
Once
internalized,
induce
intracellular
ROS
production
apoptosis
irradiation.
Subsequently,
ultrasonic
stimulation
triggered
autophagy-mediated
release
Cu
Rhein
from
CRUPPA19,
thereby
increasing
protein
lipoylation
global
mRNA
methylation,
led
cuproptosis
transcriptional
repression
PDL1,
respectively.
cascades
synergistically
induced
immunogenic
cell
death
tumors
promoted
activation
CD8+
T
cells,
leading
antilymphoma
immune
response.
CRUPPA19-mediated
sono-immunotherapy
not
only
eliminated
primary
metastatic
lymphomas
but
cleared
This
study
provided
insight
MOF-based
nanoepigenetic
platform
ultrasound-triggered
amplification
enhanced
antihematological
tumor
immunity.
Angewandte Chemie International Edition,
Journal Year:
2024,
Volume and Issue:
63(37)
Published: June 17, 2024
The
exploration
of
cell-based
drug
delivery
systems
for
cancer
therapy
has
gained
growing
attention.
Approaches
to
engineering
therapeutic
cells
with
multidrug
loading
in
an
effective,
safe,
and
precise
manner
while
preserving
their
inherent
biological
properties
remain
great
interest.
Here,
we
report
a
strategy
simultaneously
load
multiple
drugs
platelets
one-step
fusion
process.
We
demonstrate
doxorubicin
(DOX)-encapsulated
liposomes
conjugated
interleukin-15
(IL-15)
could
fuse
achieve
both
cytoplasmic
surface
cytokine
modification
efficiency
over
70
%
within
minutes.
Due
targeting
ability
metastatic
cancers
postoperative
bleeding
sites,
the
engineered
demonstrated
synergistic
effect
suppress
lung
metastasis
recurrence
mouse
B16F10
melanoma
tumor
models.
ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(47), P. 32818 - 32833
Published: Nov. 11, 2024
The
tumor
immunosuppressive
microenvironment
(TME)
induced
by
incomplete
radiofrequency
ablation
(iRFA)
in
hepatocellular
carcinoma
(HCC)
is
a
critical
driver
of
progression
and
metastasis.
Herein,
we
proposed
therapeutic
strategy
aimed
at
remodeling
the
post-iRFA
TME
targeting
exosome
biogenesis,
secretion,
PD-L1
expression,
thereby
rejuvenating
cytotoxic
T
lymphocyte
function
to
mitigate
metastasis
HCC.
Leveraging
versatile
properties
polydopamine
nanomodulators,
have
engineered
tailored
delivery
platform
for
GW4869
amlodipine
(AM),
enabling
precise
tumor-specific
release
these
agents.
Initially,
GW4869,
neutral
sphingomyelinase
inhibitor,
synergized
with
AM,
an
intracellular
calcium
modulator,
suppress
biogenesis
secretion.
Subsequently,
AM
triggered
autophagic
degradation
PD-L1.
ACS Applied Materials & Interfaces,
Journal Year:
2024,
Volume and Issue:
16(23), P. 29634 - 29644
Published: June 1, 2024
Efficient
protection
and
precise
delivery
of
biomolecules
are
critical
importance
in
the
intervention
therapy
various
diseases.
Although
diverse
specific
marker-functionalized
drug
carriers
have
been
developed
rapidly,
current
approaches
still
encounter
substantial
challenges,
including
strong
immunogenicity,
limited
target
availability,
potential
side
effects.
Herein,
we
a
biomimetic
exosome-sheathed
magnetic
mesoporous
anchor
modified
with
glucose
oxidase
(MNPs@mSiO2-GOx@EM)
to
address
these
challenges
achieve
synergistic
targeting
starving
tumor
cells.
The
MNPs@mSiO2-GOx@EM
integrated
unique
characteristics
different
components.
An
external
decoration
exosome
membrane
(EM)
high
biocompatibility
contributed
increased
phagocytosis
prevention,
prolonged
circulation,
enhanced
recognition
cellular
uptake
loaded
particles.
internal
coated
core
rapid
responsiveness
by
field
guidance
large
surface
area
facilitated
enrichment
nanoparticles
at
site
provided
enough
space
for
modification
(GOx).
inclusion
GOx
middle
layer
accelerated
energy-depletion
process
within
cells,
ultimately
leading
starvation
death
cells
minimal
With
merits,
vitro
study
manifested
that
our
nanoplatform
not
only
demonstrated
an
excellent
capability
94.37%
±
1.3%
toward
homotypic
but
also
revealed
remarkably
catalytical
ability
cytotoxicity
on
Assisted
guidance,
utilization
obviously
inhibits
growth
vivo.
Together,
is
promising
serve
as
versatile
method
highly
efficient
intended
locations
due
fungibility
membranes
provide
route
Journal of the American Chemical Society,
Journal Year:
2025,
Volume and Issue:
147(9), P. 7897 - 7907
Published: Feb. 24, 2025
Proteolysis
targeting
chimeras
(PROTACs)
represent
a
cutting-edge
approach
for
targeted
protein
degradation
in
cancer
therapy,
yet
they
face
challenges
such
as
poor
pharmacokinetics
and
specificity
issues,
leading
to
undesirable
off-target
effects
limited
antitumor
potency.
To
address
these
we
introduce
dual-targeted
unimolecular
theranostic
probes
(e.g.,
radioactive
177Lu-P-A
its
cold
counterpart
natLu-P-A)
disease-activatable
PROTACs
combination
with
radionuclide
therapy
(TRT)
against
prostate
high
effectiveness.
The
achieve
cathepsin
B
(CTSB)-activatable
pro-PROTAC
moiety
precise
of
bromodomain-containing
4
(BRD4)
prostate-specific
membrane
antigen
(PSMA)-targeted
177Lu-based
TRT.
Owing
the
favorable
PSMA-mediated
excellent
efficiency,
probe
possesses
tumor
imaging
accumulation
capacity
therapeutic
units
highly
effective
In
contrast,
free
unit
ARV-771)
shows
no
observable
effect
due
ability.
Importantly,
BRD4
proteolysis
by
PROTAC
activation
can
downregulate
radiosensitivity-associated
RAD51AP1
expression,
synergistically
enhancing
TRT
promoting
apoptosis
after
combined
compared
individual
treatment
regimes.
Additionally,
demonstrates
renal
clearance,
underscoring
biosafety
potential
clinical
translation.
This
study
presents
therapy.
